GERK, PHILLIP M.,BARR, WILLIAM, H.,RITTER, JOSEPH, K.
申请号：
CL2014000747
公开号：
CL2014000747A1
申请日:
2014.03.26
申请国别(地区):
CL
年份:
2015
代理人:
摘要：
Presystemic metabolism in intestine of bioactives such as phenylephrine is avoided by administering a subject (human or animal) the bioactive (e.g., phenylephrine) in combination with one or more inhibitors of sulfation (e.g., sulfotransferase enzymes aka SULTs). This can also be enhanced be co-administering inhibitors of monoamine oxidases aka, MAOs, and uridine diphosphate glucoronysl transferases, aka UGTs. Preferably the inhibitors are GRAS compounds. The one or more inhibitor compounds inhibit the enzymes responsible for rapid presystemic metabolism, thus allowing the bioactives (e.g., phenylephrine) to be more readily absorbed intact into the circulatory system.METODO PARA EL AUMENTO DE LA BIODISPONIBILIDAD ORAL DE UN BIOACTIVO POR MEDIO DE LA INHIBICION DE UNA O MAS SULFOTRANSFERASAS SULTS.
